SCHEMBL8201054

SCHEMBL8201054

N=C(N)c1cccc(C[C@H](NS(=O)(=O)c2cccc(NC(=O)CCN)c2)C(=O)N2CCC(CCCC(N)=O)CC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
F10 P00742 20/20 1.00
ST14 Q9Y5Y6 20/20 1.00
F2 P00734 15/20 1.00
PLG P00747 15/20 1.00
PLAU P00749 15/20 1.00
TMPRSS6 Q8IU80 5/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8190331 0.96 F10 (1.00) F10ST14F2PLGPLAU
SCHEMBL6874294 0.95 F10 (1.00) F10ST14F2PLGPLAU
SCHEMBL8197768 0.94 ST14 (1.00) F10ST14F2PLGPLAU
SCHEMBL8201049 0.94 ST14 (1.00) F10ST14F2PLGPLAU
SCHEMBL19309685 0.94 ST14 (1.00) F10ST14F2PLGPLAU
SCHEMBL14669479 0.91 F10 (0.92) F10ST14F2PLGPLAU
SCHEMBL19309580 0.91 F10 (1.00) F10ST14F2PLGPLAU
SCHEMBL12998769 0.91 F10 (1.00) F10ST14F2PLGPLAU
SCHEMBL8196664 0.90 ST14 (1.00) F10ST14F2PLGPLAU
SCHEMBL14669476 0.90 F10 (1.00) F10ST14F2PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208308-B2 Matriptase inhibitors and uses thereof against orthomyxoviridae infections SOCPRA Sciences Sante et Humaines S.E.C. (CA) 2019-02-19 US disclosed
US-20170314023-A1 MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS UNIVERSITE DE SHERBROOKE (CA) 2017-11-02 US disclosed
US-9752149-B2 Matriptase inhibitors and uses thereof against orthomyxoviridae infections SOCPRA Sciences Sante et Humaines S.E.C. (CA) 2017-09-05 US disclosed
US-8569313-B2 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2013-10-29 US disclosed
EP-2132174-B1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS MEDICINES CO LEIPZIG GMBH (DE) 2012-02-01 EP disclosed
US-20100305090-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2010-12-02 US disclosed
WO-2008107176-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305090-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS MMP7, DNPEP, METAP1 F10 1148/4885ST14 12/4885F2 1287/4885
US-10208308-B2 Matriptase inhibitors and uses thereof against orthomyxoviridae infections MMP7, MATR3, ADAMTS1 F10 321/4885ST14 96/4885F2 995/4885
US-20170314023-A1 MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS MMP7, MATR3, ADAMTS1 F10 321/4885ST14 96/4885F2 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.